Clinical trial · Observational
A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)
NCT04660617CI-TRIAL-00051716unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators plan to perform multi-omics technologies, including genomic, transcriptomic, epigenomic and proteomic methods, in patients with metastatic prostate cancer, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Genetic profiling results
- timeFrame
- From baseline (initial diagnosis of PCa), until study completion (48 months)
- description
- Mutation identified via whole-genome sequencing will be recored.
- measure
- Transcriptional profiling results
- timeFrame
- From baseline (initial diagnosis of PCa), until study completion (48 months)
- description
- Determining the transcriptomic information of metastatic prostate cancer by performing whole transcriptome sequencing
- measure
- Epigenomic profiling results
- timeFrame
- From baseline (initial diagnosis of PCa), until study completion (48 months)
- description
- Determining the epigenomic status of specific genes by performing DNA-methylation sequencing
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Pathological confirmation of prostate cancer * Age: ≥40 years old * Bone or visceral metastatic disease confirmed by image examination. * Written informed consent Exclusion Criteria: * Patients harbouring other types of cancer besides prostate cancer
References
Publications (0)
Data not yet available
No reference posted for this study.